EU Greenlights Valneva’s Chikungunya Vaccine

EU Greenlights Valneva’s Chikungunya Vaccine

The European Medicines Agency (EMA) has recommended the use of Valneva's single-shot vaccine, VLA1553, for the chikungunya virus. This follows the European Commission's approval, making it the first preventive shot for the disease approved in Europe for adults. The vaccine had previously received approval from U.S. health regulators in November 2022 and is marketed in the United States under the brand name Ixchiq.

Late-stage trials of the VLA1553 vaccine demonstrated that it could induce antibody levels capable of neutralizing the chikungunya virus in 98.9% of participants for 28 days post-vaccination. Currently, the Centers for Disease Control and Prevention (CDC) recommend rest, fluids, and the use of analgesics and antipyretics to manage chikungunya symptoms. As of 2023, there have been approximately 500,000 cases and over 400 deaths worldwide due to the disease.

Summary

Other news in health